Biotaitan Molmed CO., LTD.
Update：2026/04/22
Industries
Main Industry
Health Care
Main Product/Service
Our core product, the AcesoBox, is a point-of-care molecular testing platform that delivers multi-target, rapid, highly sensitive, and precise diagnostics, enabling testing anytime and anywhere. This next-generation ultra-fast molecular diagnostic system completes nucleic acid tests within 10–15 minutes by integrating a patented rapid thermal cycling system with multi-channel optical detection. Users simply insert minimally processed samples into reagent tubes to obtain results for 15 nucleic acid targets, covering infectious diseases, high-sensitivity myocardial infarction screening, sexually transmitted infections, sepsis, and cancer. Combining rapid PCR and immuno-PCR technologies, the system provides multi-omics insights—including genomics, transcriptomics, proteomics, and metabolomics—enhanced with AI analysis for precision medicine. Suitable for hospitals, clinics, diagnostic labs, ambulances, field use, and home environments, Titan also offers complete solutions encompassing reagent development, microfluidic cartridge design, and micro-optical detection system integration.
Founded Year
2023
Unified Business No.
83004262
Status
Active
Number of Employees
6
Total Paid-in
Capital
18,349,328 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Biotaitan Molmed, founded in 2023, develops precision medical and rapid molecular diagnostic platforms. Their technology covers multi-target molecular diagnostics, rapid thermal cycling modules, and micro-optical reading systems. Collaborating with academic institutions and hospitals, Biotaitan Molmed aims to provide high-quality, innovative diagnostic tools for smarter, faster healthcare decisions globally.
